Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.025
Neutral
RSI(14)
57.304
Neutral
STOCH(KDJ)(9,3,3)
60.910
Buy
ATR(14)
0.045
Low Volatility
CCI(14)
305.141
Overbought
Williams %R
34.304
Buy
TRIX(12,20)
-0.685
Sell
StochRSI(14)
100.000
Buy
Search
Longeveron Inc
LGVNAdd to Watchlist
0.702USD
+0.026+3.88%
Close 07-31 16:00（ET）Quotes delayed by 15 min
21.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+3.88%
5 Days
+16.92%
1 Month
-0.21%
6 Months
+25.34%
Year to Date
+38.64%
1 Year
-56.70%
Key Figures
0.700Open
0.767High
653.15KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.12%Turnover Ratio
0.675Prev. Close
0.685Low
352.59KTurnover
LossP/E Static
1.35P/B
0.00%Div Yield TTM
-106.66%ROA
1.80052wk High
3.06Volume Ratio
-24.62MNet Profit
30.78MShares
-1.1476EPS TTM
-0.34Beta
-135.18%ROE
0.47552wk Low
12.22%Amplitude
66.33%Gross Margin
21.59MMarket Cap
-0.33Reward/Risk
6.64%Risk Rate
TradingKey Stock Score of Longeveron Inc
Currency: USD Updated: 2026-07-31Key Insights
Longeveron Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.36.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Longeveron Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Longeveron Inc Highlights
StrengthsRisks
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.11% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.20M.
Fairly Valued
The company’s latest PE is -0.61, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.25M shares, increasing 33.51% quarter-over-quarter.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.362
Target Price
+969.33%
Upside Space
Longeveron Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.362
Target Price
+969.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Longeveron Inc
LGVN
3
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.637
Buy
MA10
0.623
Buy
MA20
0.630
Buy
MA50
0.712
Sell
MA100
0.828
Sell
MA200
0.728
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Longeveron Inc Info
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Ticker SymbolLGVN
CompanyLongeveron Inc
CEOPowell (Than)
Websitehttps://www.longeveron.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Longeveron Inc (LGVN)?
The current price of Longeveron Inc (LGVN) is 0.71.
What is the symbol of Longeveron Inc?
The ticker symbol of Longeveron Inc is LGVN.
What is the 52-week high of Longeveron Inc?
The 52-week high of Longeveron Inc is 1.80.
What is the 52-week low of Longeveron Inc?
The 52-week low of Longeveron Inc is 0.47.
What is the market capitalization of Longeveron Inc?
The market capitalization of Longeveron Inc is 21.88M.
Is Longeveron Inc (LGVN) currently rated as Buy, Hold, or Sell?
According to analysts, Longeveron Inc (LGVN) has an overall rating of Buy, with a price target of 6.36.
What is the Earnings Per Share (EPS TTM) of Longeveron Inc (LGVN)?
The Earnings Per Share (EPS TTM) of Longeveron Inc (LGVN) is -1.29.